Endocrine Pharmacology USMLE Step 1 Practice Question

A 64-year-old woman with a 9-year history of type 2 diabetes mellitus presents to her primary care physician for a routine follow-up. Her HbA1c is 7.8%, fasting plasma glucose is 118 mg/dL, and 2-hour postprandial glucose is 286 mg/dL, consistent with predominantly postprandial hyperglycemia. Her BMI is 29 kg/m², blood pressure is 132/84 mmHg, and renal function is intact with a serum creatinine of 0.9 mg/dL. She is started on a new oral agent that competitively inhibits intestinal brush border alpha-glucosidases, thereby delaying oligosaccharide and disaccharide hydrolysis. Within several days of initiating therapy, she develops marked bloating, excessive flatulence, and diffuse abdominal discomfort that worsens after meals. She denies diarrhea, nausea, or vomiting. Which of the following drugs was most likely prescribed?